MEDSAFE NZ Moves Ahead in 2020

Medsafe NZ has been working on a new therapeutic products regulatory regime to replace and modernise the regulatory arrangements for medicines.

Since 2015, Medsafe NZ, the  New Zealand Medicines and Medical Devices Safety Authority , has been working on a new therapeutic products regulatory regime to replace and modernise the regulatory arrangements for medicines, and provide regulation of all therapeutic products.

Whilst we are still waiting for the progression of the Therapeutic Products Bill through parliament, the Guidelines on the Regulation of Therapeutic Products in New Zealand are being modernised in parallel.

While some parts of the guidance were updated in 2018, other mooted changes seem to have been in draft for a long time. In particular, the medical device regulatory update which is still under construction on the  Medsafe New Zealand  website.

The most recent changes have been to Parts 2 (New and Changed Medicines) and 7 (Advertising) of the guidance documents. However, only minor updates were made to Part 2. These sought to clarify and regularise aspects that had previously been discussed with industry, such as acceptance of different dossier formats. The inclusion of some nice decision trees is a welcome addition.

We all had a sigh of relief to see that, while not mandatory, either NeeS (Non-eCTD electronic Submissions) OR eCTD format submissions are now possible. But, let’s not get too excited about this. Medsafe NZ does not have full functionality for eCTDs and therefore, lifecycle management is still a challenge.

Ideally, Medsafe NZ still prefer to see a hyperlinked Table of Contents, rather than an index file. And, we still have one foot in the land of paper submissions with a mandatory hardcopy of Module 1 to be provided together with two electronic copies of the full dossier (Modules 1-5).  Acceptable electronic media is limited to CDs and DVDs only.

Part 7 advertising guidance had a major update and is very clear and readable in terms of what is allowable for advertising of medical devices, medicines (prescription, OTC, restricted in New Zealand. This includes internet, mail order, point of sale and direct marketing advertisements as well as communications to health professionals.

Of note, and something that often catches out Sponsors in their website advertising, is that testimonials must not be used.

More recent articles

  • Australia and the ACCESS Consortium: Navigating Regulatory Collaboration

    Australia and the ACCESS Consortium: Navigating Regulatory Collaboration

    The Access Consortium is a coalition of like-minded regulatory authorities working together to promote greater regulatory collaboration and alignment of regulatory requirements. Learn how the ACCESS Consortium can streamline medicine approvals in Australia and partner countries, accelerating access to new therapies. Australia as an Early Entry Market for Medicines Australia is an increasingly attractive early…

  • Life Sciences Expansion Strategies Greater Bay Area – China

    Life Sciences Expansion Strategies Greater Bay Area – China

    China’s Greater Bay Area (GBA) initiative aims to create a single, integrated economic zone, fostering innovation, connectivity, and environmental sustainability. We explore how the Greater Bay Area (GBA) is transforming life sciences and medical device access in China, with regulatory benefits and streamlined market entry opportunities. What is the Greater Bay Area (GBA)? The Greater…

  • Australia’s TGA Priority Review Pathway

    Australia’s TGA Priority Review Pathway

    How Australia’s TGA Priority Review Pathway Helps Speed Up Access to New Medicines. The ultimate goal of every regulatory submission is patient access. Whether seeking approval for a new prescription medicine or an additional indication for an existing drug, the objective remains the same — providing patients with the best possible treatment options as quickly…